eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs)
eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). The company targets the eIF4F complex and its activating kinase, focusing on cancer therapeutics.